Exact Mass: 424.1556
Exact Mass Matches: 424.1556
Found 500 metabolites which its exact mass value is equals to given mass value 424.1556
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Eprosartan
Eprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It acts on the renin-angiotensin system in two ways to decrease total peripheral resistance. First, it blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist D057911 - Angiotensin Receptor Antagonists > D057912 - Angiotensin II Type 2 Receptor Blockers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 2776 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Eprosartan (SKF-108566J free base) is a selective, competitive, nonpeptid and orally active angiotensin II receptor antagonist, used as an antihypertensive. Eprosartan binds angiotensin II receptor with IC50s of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively [1].
N,N'-diacetylchitobiose
N,N-diacetylchitobiose, also known as (GlcNAc)2, is classified as a member of the Acylaminosugars. Acylaminosugars are organic compounds containing a sugar linked to a chain through N-acyl group. N,N-diacetylchitobiose is considered to be soluble (in water) and acidic. N,N-diacetylchitobiose may be a unique E.coli metabolite N,N'-Diacetylchitobiose is a dimer of β(1,4) linked N-acetyl-D glucosamine. N,N'-Diacetylchitobiose is the hydrolysate of chitin and can be used as alternative carbon source by?E. coli[1].
6-Hydroxymelatonin glucuronide
6-Hydroxymelatonin glucuronide is a metabolite of melatonin. Melatonin Listen/ˌmɛləˈtoʊnɪn/, also known chemically as N-acetyl-5-methoxytryptamine, is a naturally occurring compound found in animals, plants, and microbes. In animals, circulating levels of the hormone melatonin vary in a daily cycle, thereby allowing the entrainment of the circadian rhythms of several biological functions. (Wikipedia)
D-Cloprostenol
4-[[2-Butyl-5-(2-carboxy-3-thiophen-2-ylprop-1-enyl)-1-imidazolyl]methyl]benzoic acid
Calix[4]arene
Forsmann antigen
Galnac-1-4-glcnac
Lacdinac
N,N'-Diacetylchitobiose is a dimer of β(1,4) linked N-acetyl-D glucosamine. N,N'-Diacetylchitobiose is the hydrolysate of chitin and can be used as alternative carbon source by?E. coli[1].
SPIRADOLINE
methyl 2-((2,2-dimethylchroman-6-yl)methyl)-4-hydroxy-3-(4-hydroxyphenyl)-5-oxo-2,5-dihydrofuran-2-carboxylate
7,8,3,4-Tetramethoxy-6,6-dimethylpyrano[2,3:5,6]flavone
(+)-tephropurpurin
10,11-dioxo-aspidofractinine-1,3-dicarboxylic acid dimethyl ester|10,11-Dioxo-pleiocarpin
1,5,6-trihydroxy-7-methoxy-6,6-dimethyl-2H-pyrano (2,3:3,2)-4-(3,3-dimethylprop-2-enyl) xanthone
2-hydroxy-4-[4-hydroxyphenyl-(4-hydroxy-3-methoxybenzyl)]-3-(3,5-dihydroxyphenyl)tetrahydrofuran|pouzolignan A
2,4,5,5-tetramethoxy-2,2-dimethylpyrano<6,5-h>isoflavone|2,4,5,5-Tetramethoxy-2,2-dimethylpyrano-<6,5-h>isoflavone|5-Methoxy-8,8-dimethyl-3-(2,4,5-trimethoxy-phenyl)-8H-pyrano[2,3-f]chromen-4-on|5-methoxy-8,8-dimethyl-3-(2,4,5-trimethoxy-phenyl)-8H-pyrano[2,3-f]chromen-4-one|5-methoxybarbigerone|toxicarol
O-(3-Hydroxymethyl-2-butenyl)-3-[(4-Hydroxyphenyl)methyl]-1,4-dimethyl-3,6-bis(methylthio)-2,5-piperazinedione
angeloyl beta-D-glucopyranosyl-(1->6)-beta-D-glucopyranoside|everlastoside F
12-(1,1-dimethylallyl)-5,7,9-trihydroxy-10-methoxy-2,2-dimethyl-2H-pyrano[3,2-b]xanthen-6-one|linixanthone A
C24H24O7_Methyl (2R)-4-hydroxy-2-[4-hydroxy-3-(3-methyl-2-buten-1-yl)benzyl]-3-(4-hydroxyphenyl)-5-oxo-2,5-dihydro-2-furancarboxylate
2-oxapentacyclo[21.2.2.13,7.110,14.015,20]nonacosa-1(25),3,5,7(29),10(28),11,13,15(20),16,18,23,26-dodecaene-4,13,18-triol
CONFIDENCE Predicted
Ala Cys Met Thr
Ala Cys Thr Met
Ala Asp Gly Tyr
Ala Asp Tyr Gly
Ala Gly Asp Tyr
Ala Gly Tyr Asp
Ala Met Cys Thr
Ala Met Thr Cys
Ala Thr Cys Met
Ala Thr Met Cys
Ala Tyr Asp Gly
Ala Tyr Gly Asp
Cys Ala Met Thr
Cys Ala Thr Met
Cys Cys Ile Ser
Cys Cys Leu Ser
Cys Cys Ser Ile
Cys Cys Ser Leu
Cys Cys Thr Val
Cys Cys Val Thr
Cys Ile Cys Ser
Cys Ile Ser Cys
Cys Leu Cys Ser
Cys Leu Ser Cys
Cys Met Ala Thr
Cys Met Thr Ala
Cys Ser Cys Ile
Cys Ser Cys Leu
Cys Ser Ile Cys
Cys Ser Leu Cys
Cys Thr Ala Met
Cys Thr Cys Val
Cys Thr Met Ala
Cys Thr Thr Thr
Cys Thr Val Cys
Cys Val Cys Thr
Cys Val Thr Cys
Asp Ala Gly Tyr
Asp Ala Tyr Gly
Asp Phe Gly Ser
Asp Phe Ser Gly
Asp Gly Ala Tyr
Asp Gly Phe Ser
Asp Gly His Pro
Asp Gly Pro His
Asp Gly Ser Phe
Asp Gly Tyr Ala
Asp His Gly Pro
Asp His Pro Gly
Asp Pro Gly His
Asp Pro His Gly
Asp Ser Phe Gly
Asp Ser Gly Phe
Asp Tyr Ala Gly
Asp Tyr Gly Ala
Glu Gly Gly Tyr
Glu Gly Tyr Gly
Glu Tyr Gly Gly
Phe Asp Gly Ser
Phe Asp Ser Gly
Phe Gly Asp Ser
Phe Gly Ser Asp
Phe Ser Asp Gly
Phe Ser Gly Asp
Gly Ala Asp Tyr
Gly Ala Tyr Asp
Gly Asp Ala Tyr
Gly Asp Phe Ser
Gly Asp His Pro
Gly Asp Pro His
Gly Asp Ser Phe
Gly Asp Tyr Ala
Gly Glu Gly Tyr
Gly Glu Tyr Gly
Gly Phe Asp Ser
Gly Phe Ser Asp
Gly Gly Glu Tyr
Gly Gly Tyr Glu
Gly His Asp Pro
Gly His Pro Asp
Gly Met Met Ser
Gly Met Ser Met
Gly Pro Asp His
Gly Pro His Asp
Gly Ser Asp Phe
Gly Ser Phe Asp
Gly Ser Met Met
Gly Tyr Ala Asp
Gly Tyr Asp Ala
Gly Tyr Glu Gly
Gly Tyr Gly Glu
His Asp Gly Pro
His Asp Pro Gly
Ile Cys Cys Ser
Ile Cys Ser Cys
Ile Ser Cys Cys
Leu Cys Cys Ser
Leu Cys Ser Cys
Leu Ser Cys Cys
Met Ala Cys Thr
Met Ala Thr Cys
Met Cys Ala Thr
Met Cys Thr Ala
Met Gly Met Ser
Met Gly Ser Met
Met Met Gly Ser
Met Met Ser Gly
Met Ser Gly Met
Met Ser Met Gly
Met Ser Ser Thr
Met Ser Thr Ser
Met Thr Ala Cys
Met Thr Cys Ala
Met Thr Ser Ser
Ser Cys Cys Ile
Ser Cys Cys Leu
Ser Cys Ile Cys
Ser Cys Leu Cys
Ser Asp Phe Gly
Ser Asp Gly Phe
Ser Phe Asp Gly
Ser Phe Gly Asp
Ser Gly Asp Phe
Ser Gly Phe Asp
Ser Gly Met Met
Ser Ile Cys Cys
Ser Leu Cys Cys
Ser Met Gly Met
Ser Met Met Gly
Ser Met Ser Thr
Ser Met Thr Ser
Ser Ser Met Thr
Ser Ser Thr Met
Ser Thr Met Ser
Ser Thr Ser Met
Thr Ala Cys Met
Thr Ala Met Cys
Thr Cys Ala Met
Thr Cys Cys Val
Thr Cys Met Ala
Thr Cys Thr Thr
Thr Cys Val Cys
Thr Met Ala Cys
Thr Met Cys Ala
Thr Met Ser Ser
Thr Ser Met Ser
Thr Ser Ser Met
Thr Thr Cys Thr
Thr Thr Thr Cys
Thr Val Cys Cys
Val Cys Cys Thr
Val Cys Thr Cys
Val Thr Cys Cys
Tyr Ala Asp Gly
Tyr Ala Gly Asp
Tyr Asp Ala Gly
Tyr Asp Gly Ala
Tyr Glu Gly Gly
Tyr Gly Ala Asp
Tyr Gly Asp Ala
Tyr Gly Glu Gly
Tyr Gly Gly Glu
(+)-5-trans Cloprostenol
(+)-15-epi Cloprostenol
Cloprostenol
D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents D012102 - Reproductive Control Agents > D008186 - Luteolytic Agents
(+)-Cloprostenol
2-heptadecyl-4,5-dihydro-1H-imidazole-1-ethanol phosphate
3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-[2-[Methyl(phenylmethyl)amino]ethoxy]phenyl]-
Ethyl 4-acetoxy-5-(benzyloxy)-7,8-dimethoxy-2-naphthoate
4-[(5-carbamoyl-o-tolyl)azo]-3-hydroxynaphth-2-anilide
10-[4-(1-naphthalenyl)phenyl]-9-anthracenyl]-Boronic acid[
10-[4-(2-naphthalenyl)phenyl]-9-anthracenyl]-Boronic acid
Darotropium bromide
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent
4-([trans(trans)]-4-butyl-[1,1-bicyclohexyl]-4-yl)-1-iodo-Benzene
[trans(trans)]-1-(4-Butyl[1,1-bicyclohexyl]-4-yl)-4-iodobenzene
[4-[9-(Naphthalen-2-yl)anthracen-10-yl]phenyl]boronic acid
2-[[4-[(2-cyanoethyl)(2-phenylethyl)amino]phenyl]azo]-5-nitrobenzonitrile
N,N-Diacetylchitobiose
The N,N-diacetylated derivative of chitobiose, but with no stereodesignation for the anomeric carbon atom. N,N'-Diacetylchitobiose is a dimer of β(1,4) linked N-acetyl-D glucosamine. N,N'-Diacetylchitobiose is the hydrolysate of chitin and can be used as alternative carbon source by?E. coli[1].
4-{[1-Methyl-2,4-Dioxo-6-(3-Phenylprop-1-Yn-1-Yl)-1,4-Dihydroquinazolin-3(2h)-Yl]methyl}benzoic Acid
N,N-[biphenyl-4,4-Diyldi(2r)propane-2,1-Diyl]dimethanesulfonamide
Anileridine hydrochloride
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent
GlcNAc1-beta-3GalNAc
Ethyl 2-[2-[2-(4-methoxyanilino)-2-oxoethyl]-1-oxoisoquinolin-5-yl]oxypropanoate
4-[bis(2-methoxyethyl)sulfamoyl]-N-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)benzamide
6-Hydroxymelatonin glucuronide
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones
beta-D-GlcpNAc-(1->6)-D-GalpNAc
An amino disaccharide consisting of N-acetyl-D-galactosamine having a N-acetyl-beta-D-glucosaminyl residue attached at the 6-position.
2-Acetamido-6-O-(2-acetamido-2-deoxy-a-D-galactopyranosyl)-2-deoxy-D-galactopyranose
2-Acetamido-4-O-(2-acetamido-2-deoxy-a-D-galactopyranosyl)-2-deoxy-D-galactopyranose
SPIRADOLINE
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D045283 - Natriuretic Agents > D004232 - Diuretics
Diethyl (1r,2s,3r,4s)-5,6-Bis(4-Hydroxyphenyl)-7-Oxabicyclo[2.2.1]hept-5-Ene-2,3-Dicarboxylate
2-(3,4-dichlorophenyl)-N-methyl-N-[7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-yl]acetamide
beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc
beta-D-GalpNAc-(1->4)-D-GlcpNAc with beta configuration at the anomeric centre.
beta-D-GlcpNAc-(1->3)-alpha-D-GalpNAc
An amino disaccharide comprising an N-acetyl-beta-D-glucosamine residue linked (1->3) to an N-acetyl-beta-D-galactosamine residue at the reducing end.
beta-D-GlcpNAc-(1->6)-alpha-D-GalpNAc
beta-D-GlcpNAc-(1->6)-D-GalpNAc in which the anomeric configuration of the reducing-end GalNAc residue is alpha.
1-(3,4-dihydro-1H-isoquinolin-2-yl)-2-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methylsulfonyl]ethanone
N-[2-(2-ethyl-1-piperidinyl)ethyl]-2-[(2-methyl-1,3-benzothiazol-6-yl)sulfonylamino]acetamide
N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-alpha-D-glucosamine
Brasixanthone D
A member of the class of pyranoxanthones that is 2H,6H-pyrano[3,2-b]xanthen-6-one substituted by a 2-[(2S)-3,3-dimethyloxiran-2-yl]-2-hydroxyethyl group at position 12, hydroxy groups at positions 5 and 8 and geminal methyl groups at position 2. It is isolated from the stem bark of Calophyllum brasiliense and exhibits significant inhibitory activity against 12-O-tetradecanoylphorbol-13-acetate induced Epstein-Barr virus early antigen activation in Raji cells.
fumicycline A
An anthrafuran and meroterpenoid that is 2,3,11,11a-tetrahydroanthra[2,3-b]furan which is substituted by a 2-oxopropylidene group at position 2, a 3-methylbut-2-en-1-yl group at position 5, an oxo group at position 11, and hydroxy groups at positions 3a, 7, 9, and 10. It is one of the cryptic secondary metabolites (i.e. expressed at very low levels in the absence of specific triggers and/or conditions) of Aspergillus fumogatus, obtained following the induction of the fungus with the actinomycete Streptomyces rapamycinicus.
(5E)-N-[3-(ethylcarbamoyl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]-5-(3-methyl-6-oxocyclohexa-2,4-dien-1-ylidene)-1,2-dihydropyrazole-3-carboxamide
N-[(E)-(3-hydroxy-4-methoxyphenyl)methylideneamino]-4,6-diphenylpyrimidine-2-carboxamide
N-[5-ethyl-3-[(4-fluorophenyl)-(4-morpholinyl)methyl]-2-thiophenyl]benzamide
2-Acetamido-6-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-2-deoxy-D-glucopyranose
7,7-dimethyl-1-(4-methylphenyl)-2,5-dioxo-N-(2-oxo-3-thiolanyl)-6,8-dihydroquinoline-3-carboxamide
N-[2-(cyclohexylamino)-2-oxo-1-thiophen-2-ylethyl]-2,2,2-trifluoro-N-(4-methylphenyl)acetamide
N-acetyl-D-galactosaminyl-(1->3)-N-acetyl-D-galactosamine
beta-D-GalpNAc-(1->3)-alpha-D-GalpNAc
An amino disaccharide comprised of N-acetyl-alpha-D-galactosamine having an N-acetyl-D-galactosaminyl residue attached at the 3-position via a beta-linkage.
2-acetamido-4-O-(2-acetamido-2-deoxy-beta-D-galactopyranosyl)-2-deoxy-alpha-D-galactopyranose
(1S,5R)-7-[4-(3-methoxyphenyl)phenyl]-3-[(1-methyl-4-imidazolyl)sulfonyl]-3,6-diazabicyclo[3.1.1]heptane
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-(2-oxo-2-piperidin-1-ylethyl)-3,6-dihydro-2H-pyran-3-yl]-2-methoxybenzenesulfonamide
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-methoxybenzenesulfonamide
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-(2-oxo-2-piperidin-1-ylethyl)-3,6-dihydro-2H-pyran-3-yl]-2-methoxybenzenesulfonamide
2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-cyclopentylacetamide
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-methoxybenzenesulfonamide
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-methoxybenzenesulfonamide
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-methoxybenzenesulfonamide
2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-cyclopentylacetamide
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-methoxybenzenesulfonamide
N-[(2R,3S,6R)-6-[2-(4-cyclopropyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-4-fluorobenzenesulfonamide
N-[(2S,3S,6R)-6-[2-(4-cyclopropyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-4-fluorobenzenesulfonamide
N-[(2R,3S,6S)-6-[2-(4-cyclopropyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-4-fluorobenzenesulfonamide
2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-methoxybenzenesulfonamide
N-[(2S,3R,6S)-6-[2-(4-cyclopropyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-4-fluorobenzenesulfonamide
N-[(2R,3R,6R)-6-[2-(4-cyclopropyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-4-fluorobenzenesulfonamide
N-[(2S,3R,6R)-6-[2-(4-cyclopropyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-4-fluorobenzenesulfonamide
N-[(2S,3S,6S)-6-[2-(4-cyclopropyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-4-fluorobenzenesulfonamide
N-[(2R,3R,6S)-6-[2-(4-cyclopropyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-4-fluorobenzenesulfonamide
2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-(methanesulfonamido)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclopentylacetamide
2-acetamido-2-deoxy-D-gluco-hexopyranosyl-(1->3)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranose
N-[(Z)-(2-hydroxy-3-methoxyphenyl)methylideneamino]-4,6-diphenylpyrimidine-2-carboxamide
Eprosartan
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist D057911 - Angiotensin Receptor Antagonists > D057912 - Angiotensin II Type 2 Receptor Blockers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Eprosartan (SKF-108566J free base) is a selective, competitive, nonpeptid and orally active angiotensin II receptor antagonist, used as an antihypertensive. Eprosartan binds angiotensin II receptor with IC50s of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively [1].
beta-D-GalpNAc-(1->4)-D-GlcpNAc
An amino disaccharide consisting of N-acetylglucosamine having an N-acetylgalactosaminyl resiude attached at the 4-position via a beta-linkage.
N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-aldehydo-D-glucosamine
alpha-D-GalpNAc-(1->4)-beta-D-GlcpNAc
An alpha-D-GalpNAc-(1->4)-D-GlcpNAc in which the reducing end anomeric centre has beta-configuration.
D-GalpNAc-(1->3)-D-GalpNAc
A disaccharide composed of two 2-(acetylamino)-2-deoxy-D-galactopyranose units in (1->3) linkage.
2-Acetamido-2-deoxy-3-O-(2-acetamido-2-deoxy-B-D-glucopyranosyl)-D-galactopyranose
beta-D-GalpNAc-(1->4)-alpha-D-GalpNAc
An amino disaccharide comprised of N-acetyl-alpha-D-galactosamine having an N-acetyl-D-galactosaminyl residue attached at the 4-position via a beta-linkage. Important epitope forming part of the O-polysaccharides of some Gram-negative bacteria.
alpha-D-GalpNAc-(1->3)-D-GalpNAc
An amino disaccharide consisting of two N-acetyl-D-galactosamine units joined via an alpha-(1->3)-linkage.
alpha-D-GalpNAc-(1->4)-D-GlcpNAc
An amino disaccharide consisting of N-acetyl-D-glucosamine having an N-acetyl-alpha-D-galactosminyl resiude attached at the 4-position.
alpha-D-GalNpAc-(1->3)-beta-D-GalpNAc
An alpha-D-GalpNAc-(1->3)-D-GalpNAc having beta-configuration at the reducing end anomeric centre.
N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glucosamine
An N,N-diacetylchitobiose having beta-configuration at the reducing end anomeric centre.
RBC8
RBC8 is a novel small molecule inhibitor of Ral GTPase; has IC50 of 3.5 μM in H2122 cell and 3.4 μM in H358 cell. IC50 value: Target: Ral GTPase inhibitor RBC8 or BQU57 treatment showed no further inhibition of colony formation after Ral knockdown. RBC8 and BQU57 showed favorable properties that define good drug candidates. To test the effect of Ral inhibitors on xenograft tumor growth, nude mice were inoculated subcutaneously with H2122 human lung cancer cells and treated intraperitoneally with 50 mg/kg/d of RBC8 for 21 days (except weekends). RBC8 inhibited tumor growth to a similar extent as dual knockdown of RalA and RalB.
5,12-dihydroxy-6-methoxy-16,16-dimethyl-7-(3-methylbut-2-en-1-yl)-2,9,17-trioxatetracyclo[9.8.0.0³,⁸.0¹³,¹⁸]nonadeca-1(11),3,5,7,12,14,18-heptaen-10-one
3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl 2-methylbut-2-enoate
8-methoxy-14,14-dimethyl-6-oxo-4-phenyl-3,11,13-trioxatetracyclo[8.6.0.0²,⁷.0¹²,¹⁶]hexadeca-1(10),2(7),8-trien-15-yl acetate
4,12-bis[(2e)-but-2-en-2-yl]-6,14-dihydroxy-7,15-dimethyl-10-oxo-2,9-dioxatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaene-5-carboxylic acid
methyl 15-hydroxy-16-oxo-8,10-dioxa-13,19-diazaoctacyclo[12.8.2.1¹,¹⁵.0²,¹⁹.0³,¹⁴.0³,¹⁷.0⁴,¹².0⁷,¹¹]pentacosa-4(12),5,7(11)-triene-13-carboxylate
10,17,18-trimethoxy-7,7-dimethyl-2,8,21-trioxapentacyclo[12.8.0.0³,¹².0⁴,⁹.0¹⁵,²⁰]docosa-3,5,9,11,15(20),16,18-heptaen-13-one
1-(3,7-dimethyl-6-oxoocta-2,7-dien-1-yl)-3,6,8-trihydroxy-2-methoxyxanthen-9-one
2-oxapentacyclo[22.2.2.1³,⁷.0¹⁰,¹⁵.0¹⁶,²¹]nonacosa-1(26),3(29),4,6,10,12,14,16,18,20,24,27-dodecaene-4,12,17-triol
5,7,9-trihydroxy-10-methoxy-2,2-dimethyl-12-(2-methylbut-3-en-2-yl)-1,11-dioxatetracen-6-one
15-oxapentacyclo[20.2.2.2¹⁶,¹⁹.1¹⁰,¹⁴.0²,⁷]nonacosa-1(25),2,4,6,10,12,14(29),16,18,22(26),23,27-dodecaene-5,13,24-triol
methyl (2e,6e)-7-[2-(2-isopropyl-4,5-dihydro-1,3-thiazol-4-yl)-1,3-thiazol-4-yl]-3,5-dimethoxy-4-methylhepta-2,6-dienoate
2,15-dioxapentacyclo[22.2.2.1³,⁷.1¹⁰,¹⁴.0¹⁶,²¹]triaconta-1(26),3(30),4,6,10(29),11,13,16,18,20,24,27-dodecaene-4,17-diol
4,12-bis(but-2-en-2-yl)-6,14-dihydroxy-7,15-dimethyl-10-oxo-2,9-dioxatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaene-5-carboxylic acid
(3r,6r)-3-[(4-{[(2e)-4-hydroxy-3-methylbut-2-en-1-yl]oxy}phenyl)methyl]-1,4-dimethyl-3,6-bis(methylsulfanyl)piperazine-2,5-dione
3,6,8-trihydroxy-2-methoxy-1-(7-methyl-3-methylidene-2-oxooct-6-en-1-yl)xanthen-9-one
6-methoxy-8,8-dimethyl-3-(2,4,5-trimethoxyphenyl)pyrano[2,3-h]chromen-4-one
2,16-dioxapentacyclo[23.2.2.1³,⁷.0¹⁰,¹⁵.0¹⁷,²²]triaconta-1(27),3(30),4,6,10,12,14,17,19,21,25,28-dodecaene-4,18-diol
methyl 4-[(2,2-dimethyl-3,4-dihydro-1-benzopyran-6-yl)methyl]-2-hydroxy-3-(4-hydroxyphenyl)-5-oxofuran-2-carboxylate
14-oxapentacyclo[20.2.2.2¹⁰,¹³.1¹⁵,¹⁹.0²,⁷]nonacosa-1(25),2,4,6,10,12,15(27),16,18,22(26),23,28-dodecaene-3,16,24-triol
anticancer flavonoid pmv70p691-025
{"Ingredient_id": "HBIN016328","Ingredient_name": "anticancer flavonoid pmv70p691-025","Alias": "NA","Ingredient_formula": "C24H24O7","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1403","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}